Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics director Paul M. Silva received a new stock option grant covering 31,250 shares of Common Stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if Silva continues providing service to the company through the vesting date. Following this grant, he holds stock options for 31,250 shares directly.
Nurix Therapeutics director Edward C. Saltzman received a stock option grant for 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. All 31,250 underlying shares are reported as held directly after this award.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, assuming Mr. Saltzman continues to provide service to Nurix through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Nurix Therapeutics, Inc. director Judith A. Reinsdorf received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036. The entire award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, subject to her continued service, giving her 31,250 options beneficially owned after this grant.
Nurix Therapeutics director David L. Lacey received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and are held directly. Following this award, he holds options on 31,250 shares.
The option grant vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if he continues providing service to Nurix on that vesting date. The options expire on May 14, 2036 if not exercised.
Nurix Therapeutics director Anil Kapur received a stock option grant covering 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. This is a compensation-related award, not an open-market purchase.
The option vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as Kapur continues providing service to Nurix through the vesting date. After this grant, his directly held option position from this award totals 31,250 underlying shares.
Nurix Therapeutics, Inc. reported a Form 4 showing director Roger D. Dansey received a grant of stock options for 31,250 shares of common stock at an exercise price of $15.86 per share. The option vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to continued service, and expires on May 14, 2036. This is a compensation-related award, not an open-market trade.
Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036, providing long-term equity-based compensation.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, so long as Baynes continues to provide service through the vesting date. After this grant, he holds 31,250 derivative securities linked to Nurix common stock directly.
Nurix Therapeutics, Inc. director Julia P. Gregory received a grant of stock options covering 31,250 shares of common stock. These options have an exercise price of $15.8600 per share and expire on May 14, 2036.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as she continues providing service to the company through that vesting date. This is a compensation-related grant, not an open-market purchase or sale.
Nurix Therapeutics reports Vestal Point Capital and Ryan Wilder collectively hold 6,500,000 shares of Common Stock. The filing states this equals 6.3% of outstanding common stock, based on 103,405,813 shares outstanding as of March 20, 2026. Vestal Point Capital, LP is listed as the investment manager for the fund and account holding the shares; Mr. Wilder is disclosed as CIO and Managing Partner and signs the joint filing agreement.
Nurix Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held online. A quorum was reached, with 83,747,013 shares of common stock present, representing approximately 80.98% of the voting power entitled to vote as of March 20, 2026.
Stockholders elected three Class III directors—Arthur T. Sands, M.D., Ph.D., Roger Dansey, M.D., and Paul M. Silva—to three-year terms ending at the 2029 annual meeting. Each will serve until a successor is elected and qualified or earlier resignation or removal.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending November 30, 2026. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.